-

Agilent Presents Boehringer Ingelheim With Inaugural 2025 Instrument Trade‑In Impact Award

Award honors leadership in sustainable laboratory practices and circular economy advancement

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Boehringer Ingelheim has been selected as the winner of Agilent’s inaugural Instrument Trade‑In Impact Award, recognizing exceptional sustainability leadership demonstrated through their participation in Agilent’s trade‑in and buyback program.

The annual award honors the global partner that achieves the highest sustainability impact by diverting end‑of‑life laboratory instruments from landfill and contributing to the circular use of scientific equipment. In 2025, Boehringer Ingelheim led all partners in responsible trade‑in activity, ensuring that retired instruments were reused, refurbished, or properly recycled.

“Boehringer Ingelheim’s commitment to sustainability exemplifies how industry partnerships can accelerate measurable environmental progress,” said Joydeep Ganguly, Agilent’s Chief Operations and Quality Officer, and ESG Chair. “Their efforts directly support Agilent’s mission to advance a circular economy by extending the life of scientific instrumentation and reducing environmental impact across the value chain.”

Through their 2025 trade‑in activity, Boehringer Ingelheim diverted 6,600 kg of instrument waste from landfill—representing the highest recovery value of any Agilent partner for the year. Their leadership sets a strong example for sustainable procurement and lifecycle management across the scientific community.

"Sustainability is a strategic priority at Boehringer Ingelheim, guiding how we operate our laboratories and manage resources across their full lifecycle. Our long‑term commitment to the circular economy focuses on reducing waste and creating a measurable impact. Partnering with Agilent helps us turn this ambition into action and advance more sustainable laboratory practices together," said Yulia Ovchinnikova, Head of Global Sourcing Area Indirect at Boehringer Ingelheim.

The Instrument Trade‑In Impact Award is part of Agilent’s broader focus on supporting customer sustainability goals through reuse pathways, energy‑efficient technologies, and programs designed to reduce laboratory waste and promote circular economy practices.

About Agilent Technologies

Agilent Technologies, Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.95 billion in fiscal year 2025 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

Media Contact:
Kate Coyle
Agilent Technologies Inc.
+1 302-633-7490
kate.coyle@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

Media Contact:
Kate Coyle
Agilent Technologies Inc.
+1 302-633-7490
kate.coyle@agilent.com

Social Media Profiles
More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. PD-L1 IHC 22C3 pharm...

Agilent Announces Cash Dividend of 25.5 Cents per Share

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a quarterly dividend of 25.5 cents per share of common stock. The quarterly dividend will be paid on April 22, 2026, to all shareholders of record as of the close of business on March 31, 2026. The timing and amounts of future dividends are subject to the determination and approval of Agilent’s board of directors. About Agilent Technologies Agilent Technologies, Inc. (NYSE: A) is a global leader in analyti...

Agilent Showcases Next‑Generation Automated Solutions at SLAS2026

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that it will present a range of next‑generation automated workflow innovations at the SLAS2026 International Conference & Exhibition, taking place February 7–11 in Boston, Massachusetts. Agilent will demonstrate how its expanding automation ecosystem—integrating advanced imaging, software, robotics, and AI‑powered optimization—supports laboratories in accelerating discovery with confidence, efficiency,...
Back to Newsroom